TY  - GEN
AU  - Mackay,H J
AU  - Buckanovich,R J
AU  - Hirte,H
AU  - Correa,R
AU  - Hoskins,P
AU  - Biagi,J
AU  - Martin,L P
AU  - Fleming,G F
AU  - Morgan,R
AU  - Wang,L
AU  - Polintan,R
AU  - Oza,A M
TI  - A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia
SN  - 1095-6859
PY  - 2012///0713
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - California
KW  - Carcinosarcoma
KW  - drug therapy
KW  - Chicago
KW  - Disease-Free Survival
KW  - Drug Administration Schedule
KW  - Female
KW  - Genital Neoplasms, Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Leiomyosarcoma
KW  - Middle Aged
KW  - Receptors, Vascular Endothelial Growth Factor
KW  - Recombinant Fusion Proteins
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1016/j.ygyno.2011.11.042
ER  -